Comparison of effects of EPA and DHA in patients with type 2 diabetes

Comparison of effects of ecosapentaenoic acid and docosahexaenoic acid on blood glucose, fat mass, MDA and C-reactive protein in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138812102394N4

Enrollment

Registered

2011-06-06

Start date

2010-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: eicosapentaenoic acid: 1000 mg daily (four 250 mg soft gels) 2 times a day (at lunch time and dinner time) for 12 weeks. Intervention 2: docosahexaenoic acid: 1000 mg daily (four 2

Treatment - Other

Placebo

eicosapentaenoic acid: 1000 mg daily (four 250 mg soft gels) 2 times a day (at lunch time and dinner time) for 12 weeks

docosahexaenoic acid: 1000 mg daily (four 250 mg soft gels) 2 times a day (at lunch time and dinner time) for 12 weeks

Placebo : canola oil 1000 mg daily (four 250 mg soft gels) 2 times a day (at lunch time and dinner time) for 12 weeks

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Age: 35-65years; 2- Willing to participate; 3- Having diabetes type 2 for at least five years prior to entry; 4- Blood sugar control with biguanide and sulfonylurea drugs for at least of one year prior to entry; 5- Normal blood pressure and lipid profile; 6- BMI : 20-35 kg/m2; Exclusion criteria: 1- Treatment with insulin; 2- Taking fish oil supplements or NSAIDs during the last 3 months before intervention; 3- Taking fish more than once a week; 4- Having cardiovascular, liver, kidney disease; 5- Smoking; 6- Weight changes more than three kilograms during three months before intervention; 7- Change in type or dose of oral hypoglycemic agent for at least two weeks prior to entry or during intervention;

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: at baseline, after 12 weeks. Method of measurement: enzymatic colorimetric.;Fat mass. Timepoint: at baseline, after 12 weeks. Method of measurement: BIA.;Malondialdehyde. Timepoint: at baseline, after 12 weeks. Method of measurement: ELISA.;C-reactive protein. Timepoint: at baseline, after 12 weeks. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026